



## Voyager Therapeutics to Present at Investor Conferences in November

November 13, 2017

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:

- **Stifel 2017 Healthcare Conference, New York City**

**Date:** Wednesday, November 15, 2017

**Time:** 2:00 p.m. EST

**Panel Members:** Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer

- **Piper Jaffray Healthcare Conference, New York City**

**Date:** Tuesday, November 28, 2017

**Time:** 9:00 a.m. EST

**Panel Members:** Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer

- **Evercore ISI Biopharma Catalyst/Deep Dive Conference, Boston, MA**

**Date:** Wednesday, November 29, 2017

**Time:** 3:30 p.m. EST

**Panel Members:** Steven Paul, M.D., president and chief executive officer and Jane Henderson, chief financial officer and senior vice president of corporate development

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager's website at [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com). The webcast will be archived for 30 days after the live event concludes.

### About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company's pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of ALS, Huntington's disease, Friedreich's ataxia, frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com).

### Investor Relations:

Matt Osborne

Vice President of Investor Relations & Corporate Communications

857-259-5353

[mosborne@vygr.com](mailto:mosborne@vygr.com)

### Media:

Katie Engleman

Pure Communications, Inc.

910-509-3977

[Katie@purecommunicationsinc.com](mailto:Katie@purecommunicationsinc.com)

Voyager Therapeutics, Inc.